Information Provided By:
Fly News Breaks for March 21, 2018
LOXO
Mar 21, 2018 | 08:36 EDT
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Loxo Oncology to Equal Weight from Overweight as part of a rebalancing after a "strong run" for small-to-mid cap biotech stocks. While Harrison said he has more conviction in the RET market, he also believes clinical data needs to catch-up with the current valuation. However, he raised his price target on Loxo shares to $130 from $103.
News For LOXO From the Last 2 Days
There are no results for your query LOXO